Relatlimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | LAG3 |
| Clinical data | |
| Other names | BMS-986016 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6472H9922N1710O2024S38 |
| Molar mass | 145288.79 g·mol−1 |
https://www.nejm.org/doi/10.1056/NEJMoa2109970
Relatlimab (INN; development code BMS-986016) is a monoclonal antibody designed for the treatment of melanoma.[1][2][3][4]
This drug is being developed by Bristol-Myers Squibb. As of 2018, relatlimab is undergoing Phase II/III trials.[5]
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Relatlimab, American Medical Association.
- ↑ World Health Organization (2018). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 119" (PDF). WHO Drug Information. 32 (2).
- ↑ Cavagnaro JA, Cosenza ME, eds. (2021). Translational Medicine: Optimizing Preclinical Safety Evaluation of Biopharmaceuticals. Boca Raton, Florida: CRC Press. ISBN 978-1-00-047185-4.
- ↑ Robert C (December 2021). "LAG-3 and PD-1 blockade raises the bar for melanoma". Nature Cancer. 2 (12): 1251–3. doi:10.1038/s43018-021-00276-8.
- ↑ Clinical trial number NCT03704077 for "An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma" at ClinicalTrials.gov
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.